Covaxin Trial On Children Begins At AIIMS Patna: Report

Covaxin, one of the first two deployed in India's Covid inoculation drive, is an indigenously developed vaccine.

In anticipation of the arrival of a mutated variant, making minors vulnerable to COVID-19, India has begun the clinical trial of Bharat Biotech's Covaxin on children. The testing is being done at the All India Institute of Medical Sciences (AIIMS) Patna, Prasar Bharati said today in a tweet. Clinical trial of Bharat Biotech's Covaxin on children has begun at AIIMS Patna. Covaxin is a vaccine indigenously developed by the Hyderabad-based company, in association with the Indian Council of Medical Research. It was one of the first two deployed by the Centre in its nationwide Covid inoculation drive. The phase II/III clinical trials of Covaxin will be done on those aged between two and 18, senior NITI Aayog member VK Paul had announced last month, with the Centre giving its clearance on May 13. The trial was to be conducted on 525 subjects, according to him.